How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First?Half Deficit

Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.41. Over the first half of 2026, however, Xencor’s net loss widened to US$150.65 million and loss per share to US$1.99, highlighting a tension between short-term quarterly progress and heavier year-to-date spending. We’ll now consider how this quarterly...

Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 - Slideshow

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript

Xencor: Technologieplattform hilft Giganten wie Novartis und Amgen bei der Krebsbekämpfung

Krebs zählt weltweit zu den führenden Todesursachen, wobei die Zahl der Neuerkrankungen unter anderem aufgrund der steigenden Lebenserwartung weiter zunimmt. Neue Technologien wie Gen- und Zelltherapien,...

Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript